Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Angela Brogan

Nurse Practitioner, Psychiatric/Mental Health Kahului, HI Nurse Practitioner

NPI 1487279105 CMS profile 10525156

203 Hoohana St Ste 303, Kahului, HI 96732

Open in the dashboard

General payments

$3,895

221 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Angela Brogan of Kahului, HI is reported in the CMS Open Payments database as having received $3,895 across 221 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14 1
2024 General $850 56
2023 General $1,426 83
2022 General $779 35
2021 General $826 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Angela Brogan
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Angela Brogan were reported at $14. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Angela Brogan Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $826 $166 $54–$482 $132
2022 $779 $195 $66–$559 $149
2023 $1,426 $233 $82–$673 $160
2024 $850 $236 $84–$688 $164
2025 $14 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Teva Pharmaceuticals USA, Inc. $744 45 payments
  2. Alkermes, Inc. $664 31 payments
  3. AbbVie, Inc. $579 37 payments
  4. Janssen Pharmaceuticals, Inc $382 22 payments
  5. Otsuka America Pharmaceutical, Inc. $281 16 payments
  6. Neurocrine Biosciences, Inc. $274 12 payments
  7. Lundbeck LLC $210 12 payments
  8. ITI, Inc. $176 10 payments
  9. Ironshore Pharmaceuticals Inc. $117 6 payments
  10. Axsome Therapeutics, Inc. $78 4 payments
  11. Other $390 26 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,724 219 payments
  2. Education $171 2 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $579 37 payments
  2. ARISTADA Cns $549 28 payments
  3. ARISTADA Cns $549 28 payments
  4. ARISTADA Cns $439 21 payments
  5. ARISTADA Cns $439 21 payments
  6. ARISTADA INITIO $378 17 payments
  7. LYBALVI Cns $377 20 payments
  8. INVEGA $245 14 payments
  9. LYBALVI Cns $207 9 payments
  10. AUSTEDO $188 12 payments
  11. Other $2,395 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

1,907

Median for Nurse Practitioner: 389

Drug cost

$302,020

Median for Nurse Practitioner: $21,885

Branded share of claims

20.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Xr Deutetrabenazine Brand 16 $114,364
Rexulti Brexpiprazole Brand 34 $51,846
Invega Sustenna Paliperidone Palmitate Brand 16 $39,286
Vraylar Cariprazine Hcl Brand 26 $36,827
Trintellix Vortioxetine Hydrobromide Brand 24 $11,787
Paliperidone Er Paliperidone Brand 12 $4,340
Atomoxetine Hcl Generic 27 $3,934
Ziprasidone Hcl Generic 26 $3,502
Divalproex Sodium Er Divalproex Sodium Brand 61 $3,429
Doxepin Hcl Generic 21 $3,145

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$15,426

Medicare's payments for the services billed

Medicare patients

51

Average age 48

Services billed

245

21 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 41%
High blood pressure 29%
Diabetes 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $255
$255 26 —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $138
$138 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $60
$60 16 —
REXULTI
  • Lundbeck LLC $36
  • Otsuka America Pharmaceutical, Inc. $17
$53 34 —
CAPLYTA
  • ITI, Inc. $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record